117 related articles for article (PubMed ID: 34802981)
41. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
[TBL] [Abstract][Full Text] [Related]
42. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
[TBL] [Abstract][Full Text] [Related]
43. Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.
Tang K; Jin Q; Yan W; Zhang W; You G; Liu Y; Jiang T
Med Oncol; 2012 Jun; 29(2):1292-6. PubMed ID: 21394635
[TBL] [Abstract][Full Text] [Related]
44. The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis.
Zhang K; Wang XQ; Zhou B; Zhang L
Fam Cancer; 2013 Sep; 12(3):449-58. PubMed ID: 23397067
[TBL] [Abstract][Full Text] [Related]
45. Genetic secrets of long-term glioblastoma survivors.
Jovčevska I
Bosn J Basic Med Sci; 2019 May; 19(2):116-124. PubMed ID: 30114377
[TBL] [Abstract][Full Text] [Related]
46. Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
Iliadis G; Kotoula V; Chatzisotiriou A; Televantou D; Eleftheraki AG; Lambaki S; Misailidou D; Selviaridis P; Fountzilas G
BMC Cancer; 2012 Jan; 12():3. PubMed ID: 22214427
[TBL] [Abstract][Full Text] [Related]
47. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W
Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808
[TBL] [Abstract][Full Text] [Related]
48. Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma.
Hanihara M; Miyake K; Watanabe A; Yamada Y; Oishi N; Kawataki T; Inukai T; Kondo T; Kinouchi H
Clin Epigenetics; 2020 Nov; 12(1):174. PubMed ID: 33203454
[TBL] [Abstract][Full Text] [Related]
49. MGMT Status as a Clinical Biomarker in Glioblastoma.
Butler M; Pongor L; Su YT; Xi L; Raffeld M; Quezado M; Trepel J; Aldape K; Pommier Y; Wu J
Trends Cancer; 2020 May; 6(5):380-391. PubMed ID: 32348734
[TBL] [Abstract][Full Text] [Related]
50. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H
J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115
[TBL] [Abstract][Full Text] [Related]
51. Long-term survivors of glioblastoma: clinical features and molecular analysis.
Sonoda Y; Kumabe T; Watanabe M; Nakazato Y; Inoue T; Kanamori M; Tominaga T
Acta Neurochir (Wien); 2009 Nov; 151(11):1349-58. PubMed ID: 19730774
[TBL] [Abstract][Full Text] [Related]
52. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
53. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
[TBL] [Abstract][Full Text] [Related]
54. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
55. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
56. MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?
Della Puppa A; Persano L; Masi G; Rampazzo E; Sinigaglia A; Pistollato F; Denaro L; Barzon L; Palù G; Basso G; Scienza R; d'Avella D
J Neurooncol; 2012 Jan; 106(1):33-41. PubMed ID: 21725802
[TBL] [Abstract][Full Text] [Related]
57. High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma.
Braczynski AK; Capper D; Jones DTW; Schittenhelm J; Stichel D; von Deimling A; Harter PN; Mittelbronn M
Pathol Res Pract; 2020 Jan; 216(1):152728. PubMed ID: 31784096
[TBL] [Abstract][Full Text] [Related]
58. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
[TBL] [Abstract][Full Text] [Related]
59. Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.
Wick W; Steinbach JP; Platten M; Hartmann C; Wenz F; von Deimling A; Shei P; Moreau-Donnet V; Stoffregen C; Combs SE
Neuro Oncol; 2013 Oct; 15(10):1405-12. PubMed ID: 23911595
[TBL] [Abstract][Full Text] [Related]
60. Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method.
von Rosenstiel C; Wiestler B; Haller B; Schmidt-Graf F; Gempt J; Bettstetter M; Rihani L; Wu W; Meyer B; Schlegel J; Liesche-Starnecker F
J Clin Pathol; 2020 Feb; 73(2):112-115. PubMed ID: 31422371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
